Friday, November 16, 2018
While campaigning for president, Trump pledged to take action to generally reduce drug prices and to allow Medicare to negotiate lower prices for prescription medications. He then appointed a former pharmaceutical executive to run the Department of Health and Human Services, and slammed the Medicare negotiation concept after a meeting with pharmaceutical executives.
An Associated Press analysis of brand-name prescription drug prices shows it's been business as usual for drugmakers, with far more price hikes than cuts. The number of increases slowed somewhat and were not quite as steep as in past years, the AP found.
Admin's note: Participants in this discussion must follow the site's moderation policy. Profanity will be filtered. Abusive conduct is not allowed.